<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04195100</url>
  </required_header>
  <id_info>
    <org_study_id>METC18-071</org_study_id>
    <nct_id>NCT04195100</nct_id>
  </id_info>
  <brief_title>Local Pilocarpine for Relieving Dry Mouth</brief_title>
  <official_title>Local Application of Pilocarpine for Relieving Dry Mouth Complaints: A Randomized Controlled Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators intended for this study to deliver the &quot;proof-of-concept&quot; that locally
      administered pilocarpine drops in two doses are effective in a population of elderly (aged ≥
      70 years) with xerostomia at the expense of limited adverse events. To this end, the study
      aims to quantify the effect size of pilocarpine in two different dosages. In case the
      investigators observe clinically meaningful changes in xerostomia through measured NRS, a
      sufficiently-powered RCT will be prepared to compare pilocarpine to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Actual">January 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in xerostomia score (Numeric Rating Scale)</measure>
    <time_frame>3 weeks</time_frame>
    <description>The Numeric Rating Scale is used to quantify the level of severity of xerostomia using a 0-10 cm Numeric Rating Scale ranging from 0 = no dry mouth to 10 = worst possible dry mouth</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in oral health-related quality of life (Dutch Geriatric Oral Health Assessment Index)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Questionnaires assessing Oral health-related quality of life of adults, in particular older people is measured 4 times during this study by the doctor/research nurse . It comprises 12 items that measure three dimensions of Oral health-related quality of life: physical function items, psychosocial function and pain/discomfort.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>3 weeks</time_frame>
    <description>adverse events or other symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global perceived effect</measure>
    <time_frame>3 weeks</time_frame>
    <description>The Global perceived effect scale asks the patient to rate, on a numerical scale, how much their condition has improved or deteriorated since some predefined time point.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Patients of Advanced Age (≥ 70 Years) With a Clinical Diagnosis of Chronic Dry Mouth</condition>
  <arm_group>
    <arm_group_label>Low dose pilocarpine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>low dose pilocarpine = 3 x 2.0 mg = 3 x 2 drops of pilocarpine 20.0 mg/ml (2%) per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose pilocarpine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>high dose pilocarpine = 3 x 5.0 mg = 3 x 5 drops of pilocarpine 20.0 mg/ml (2%) per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pilocarpine Ophthalmic Solution</intervention_name>
    <description>low dose pilocarpine = 3 x 2.0 mg = 3 x 2 drops of pilocarpine 20.0 mg/ml (2%) per day
high dose pilocarpine = 3 x 5.0 mg = 3 x 5 drops of pilocarpine 20.0 mg/ml (2%) per day</description>
    <arm_group_label>High dose pilocarpine</arm_group_label>
    <arm_group_label>Low dose pilocarpine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 70 years of age

          -  Clinical diagnosis of chronic dry mouth defined as a Numeric Rating Scale (NRS) score
             ≥ 5 (scale 0 - 10, with 0 = no dry mouth and 10= worst possible dry mouth) on severity
             of xerostomia for more than 3 months.

        Exclusion Criteria:

          -  Existence of cognitive impairment and/or diagnosis of dementia appraised by treating
             physician

          -  Inability to fill out the questionnaires due to other reasons

          -  Prior radiation therapy of the head-and-neck region

          -  Known m. Sjögren disease

          -  Contra-indications for parasympathicomimetics (uncontrolled asthma, acute heart
             failure, active peptic ulceration, known hypersensitivity to pilocarpine, and when
             miosis is undesirable, e.g., in acute iritis and in narrow-angle (angle closure)
             glaucoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marieke van den Beuken, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Centre</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6202 AZ Maastricht</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Xerostomia</keyword>
  <keyword>Pilocarpine</keyword>
  <keyword>advanced age (≥ 70 years)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Xerostomia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Pilocarpine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT04195100/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

